Clinical Pharmacokinetics of Zidovudine

Andrews JC, McManus M, Rogers G. AZT Collaborative Working Group. Clinical benefits of concurrent administration of zidovudine and therapy for the suppression of Pneumocystis carinii. Fourth International Conference on AIDS, Stockholm, Vol. 1, p. 412, 1988 Balis F, Pizzo P, Murphy R, Eddy J, Falloon J, et al. The pharmacokinetics of azidothymidine (AZT) administered by IV bolus (IVB) and continuous infusion (CI) in children with HIV infection. Proceedings of the American Society for Clinical Oncology 7: 1, 1988 Blum MR, Lao SHT, Good SS, deMiranda P. Pharmacokinetics and bioavailability of zidovudine in humans. American Journal of Medicine 85 (Suppl. 2A): 189–194, 1988 Collaborative AZT Study Group. Activity of reduced AZT regimen. Fourth International Conference on AIDS, Stockholm, Vol. 1, p. 258, 1988a Collaborative AZT Study Group. Activity and tolerance of AZT. Fourth International Conference on AIDS, Stockholm, Vol. 2, p. 169, 1988b Collins JM, Klecker Jr RW, Kelley JA, Roth JS, McCully CL, et al. Pyrimidine dideoxyribonucleosides: selective penetration into cerebrospinal fluid. Journal of Pharmacology and Experimental Therapeutics 245: 466–470, 1988 Dutton GJ. Developmental aspects of drug conjugation with special reference to glucuronidation. Annual Review of Pharmacology and Toxicology 18: 17–35, 1978 Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine 317: 185–191, 1987 Fletcher CV, Chinnock B, Henry K, Balfour Jr HH. A pharmacokinetic model for zidovudine in semen. Fourth International Conference on AIDS, Stockholm, Vol. 2, p. 180, 1988 Freireich EJ, Gehan EA, Rall DP, et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemotherapy Reports 50: 219–244, 1966 Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proceedings of the National Academy of Sciences (USA) 83: 8333–8337, 1986 Good SS, Durack DT, deMiranda P. Biotransformation in various species and in humans of 3′-azido-3′-deoxythymidine, a potential agent for treatment of AIDS. Federation Proceedings 45: 444, 1986 Hagler DN, Frame PT. Azidothymidine neurotoxicity. Lancet 2: 1392–1393, 1986 Henry K, Chinnock BJ, Quinn RP, Fletcher CV, deMiranda P, et al. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. Journal of the American Medical Association 259: 3023–3026, 1988 Klecker RW, Collins JM, Yarchoan R, Thomas R, Jenkins JF, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clinical Pharmacology and Therapeutics 41: 407–412, 1987 Kornhauser DK, Petty BG, Woods AS, Nerhood LJ, Hendrix CW, et al. Effects of quinine sulfate and probenecid — alone and in combination — on the pharmacokinetics of zidovudine. Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 371, 1988 Langtry HD, Campoli-Richards DM. Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 37: 408–450, 1989 Laskin OL, deMiranda P, Kaiman CM, Kelley KM, Blum MR. Steady-state zidovudine (azidothymidine) pharmacokinetics in patients with AIDS and AIDS related complex. Clinical Research 36: 366A, 1988 Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Nusinoff-Lehrman S, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus in vitro. Proceedings of the National Academy of Sciences (USA) 82: 7096–7100, 1985 Morse GD, Olson J, Taylor C, Reichman RC. Multiple-dose zidovudine kinetics in hemophilia patients with liver dysfunction and human immunodeficiency virus (HIV). Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 370, 1988 Pioger JC, Taburet AM, Fillastre JP, Singlas E. Pharmacokinetics of zidovudine (AZT) and its glucuronide in healthy volunteers and in uraemic patients. Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 372, 1988 Pizzo PA, Eddy J, Falloon J, Balis F, Murphy RF, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. New England Journal of Medicine 319: 889–896, 1988 Reidenberg MM. The biotransformation of drugs in renal failure. American Journal of Medicine 62: 482–485, 1977 Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. New England Journal of Medicine 317: 192–197, 1987 Ruprecht RM, Sharpe AH, Andersen J, Jaenisch R. Therapy against neurotropic retroviruses: a rapid murine model involving transplacental or neonatal infection. In Bolognesi D (Ed.) Human retroviruses, cancer, and AIDS, pp. 447–461, AR Liss, New York, 1988 Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics 5: 445–479, 1977 Sommadossi JP, Carlisle R. Toxicity of 3′-azido-3′-deoxythymi-dine and 9-(l,3-dihydroxy-2-propoxymethyl) guanine for normal human hematopoietic progenitor cells in vivo. Antimicrobial Agents and Chemotherapy 31: 452–454, 1987 Spear JB, Kessler HA, Nusinoff-Lehrman S, deMiranda P. Zidovudine overdose. Annals of Internal Medicine 109: 76–77, 1988 Surbone A, Yarchoan R, McAtee N, Blum MR, et al. Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3′-azido-2′,3′-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study. Annals of Internal Medicine 108: 534–540, 1988 Unadkat JD, Lopez AA, Schumann L. Transplacental transfer and the pharmacokinetics of zidovudine (ZDV) in the near term pregnant macaque. Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, p. 372, 1988a Unadkat JD, Schumann L. A possible mechanism by which acetaminophen may potentiate the hematotoxicity of zidovudine (ZDV or AZT). Fourth International Conference on AIDS, Stockholm, Vol. 2, p. 181, 1988 Unadkat JD, Tartaglione T, Opheim K, Collier A, Cummings D, et al. Estimation of population pharmacokinetic parameters of zidovudine (ZDV or AZT) from AIDS patients enrolled in phase II/III trial. Fourth International Conference on AIDS, Stockholm, Vol. 2, p. 176, 1988b Vogt MW, Hartshorn KL, Furman PA, Chou TC, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 235: 1376–1379, 1987 Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, et al. Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1: 575–580, 1986 Yarchoan R, Thomas RV, Fischl MA, Grafman J, Wichman A, et al. Treatment of human immunodeficiency virus-associated neurological disease with 3′-azido-3′-deoxythymidine. In Bolognesi D (Ed.) Human retroviruses, cancer, and AIDS, pp. 393–406, AR Liss, New York, 1987 Zimmerman TP, Mahony WB, Prus KL. 3′-Azido-3′-deoxythymidine: an unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by non-facilitated diffusion. Journal of Biological Chemistry 262: 5748–5754, 1987